MIST trades 383.9% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MIST achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Milestone Pharmaceuticals Inc. (MIST) has a Wall Street consensus price target of $6.00, based on estimates from 7 covering analysts. With the stock currently trading at $1.24, this represents a potential upside of +383.9%. The company has a market capitalization of $107M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MIST trades at a trailing P/E of -1.7x. Analysts expect EPS to grow -77.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
XENEXenon Pharmaceuticals Inc. | $4.7B | $59.74 | $85.00 | +42.3% | Buy | — | 22 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
IDYAIDEAYA Biosciences, Inc. | $3.2B | $36.74 | $58.67 | +59.7% | Buy | — | 25 |
ARDXArdelyx, Inc. | $1.4B | $5.55 | $17.00 | +206.3% | Buy | — | 16 |
LXRXLexicon Pharmaceuticals, Inc. | $1.1B | $2.55 | $6.00 | +135.3% | Hold | — | 14 |
FLGTFulgent Genetics, Inc. | $567M | $19.96 | $15.00 | -24.8% | Buy | — | 9 |
NKTRNektar Therapeutics | $1.2B | $63.65 | $149.60 | +135.0% | Buy | — | 33 |
PTGXProtagonist Therapeutics, Inc. | $7.8B | $121.88 | $117.25 | -3.8% | Buy | 30.2x | 26 |
Quick answers to the most common questions about buying MIST stock.
The consensus Wall Street price target for MIST is $6, representing 383.9% upside from the current price of $1.24. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MIST has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies 383.9% upside from current levels.
MIST's current price is $1.24 with a consensus target of $6 (383.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for MIST, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
MIST is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MIST stock forecast based on 7 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MIST, with a "Buy" consensus rating and $6 price target (383.9% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MIST analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.